Navigation Links
It's in the genes: Study opens door to new treatment of the blues

A Florida State University scientist used a gene transfer technique to block the expression of a gene associated with clinical depression in a new study of mice that could lead to better treatment of human beings with this condition.

Carlos Bolanos, an assistant professor of psychology and neuroscience, was among a team of researchers that identified the role of a gene called Brain Derived Neurotrophic Factor (BDNF) in the development of social aversion. Mice treated with a transfer technique to block expression of the BDNF gene in a small area of the mid-brain did not develop the aversion despite repeated encounters with aggressive rodents. The study will be published in the Feb. 10 issue of the journal Science.

"It's very exciting because we are slowly but surely identifying mechanisms in the brain underlying psychiatric disorders that have a social withdrawal component, such as social phobia, depression and post-traumatic stress disorder, and that will allow us to find better ways to treat these disorders," Bolanos said. "This study is significant because it gives us an animal model of the disorder and opens up new areas of study."

In the experiment, the researchers subjected mice to daily bouts of social threats and subordination by aggressive rodents and continuous sensory contact with the aggressors for 10 days. Afterward, the defeated mice avoided any social contact by spending most of their time in the corner of their cages opposite other mice, including those that had not been aggressive toward them.

The defeated mice also displayed little interest in sexual interaction and showed decreased preference for palatable sugary drinks over plain water. A month later, the rodents' interest in sex and sweets had returned, but the social avoidance remained.

The researchers found that long-term use of antidepressants, such as fluoxetine (Prozac) and imipramine (Trofanil), were successful in reversing the social withdrawal in the se mice. But the successful use of the gene therapy approach to block the expression of the BDNF gene in a highly localized area of the brain suggests the potential for the development of new drug therapies with fewer side effects.

"We have made great progress in our understanding of how antidepressants work, but despite years of research, our knowledge of the changes that these drugs induce in the brain is rudimentary," Bolanos said. "Though available treatments for depression are generally safe and effective, they are still not ideal. It takes long-term treatment before seeing clinical benefit, and potential side effects are a serious problem. The findings of this study provide exciting new leads and point to potential strategies, such as developing drugs capable of targeting specific proteins in restricted brain areas."


'"/>

Source:Florida State University


Related biology news :

1. Beyond genes: Lipid helps cell wall protein fold into proper shape
2. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
3. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
4. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
5. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
6. Study Links Ebola Outbreaks To Animal Carcasses
7. Breakthrough Microarray-based Technology for the Study of Cancer
8. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
9. Study finds more than one-third of human genome regulated by RNA
10. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
11. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition Market ... Application Area, End User, And Region - Global Forecast to 2021", published by ... 2016 to USD 36.07 Billion by 2021, at a Compound Annual Growth Rate ... ... MarketsandMarkets Logo ...
(Date:12/6/2016)... Valencell , the leading innovator in ... a third consecutive year of triple digit growth for ... with a 360 percent increase in companies who have ... driven by sales of its wrist and ear Benchmark™ ... technology for hearables for fitness and healthcare applications. ...
(Date:11/30/2016)... , Nov. 30, 2016 Not many of us realize that we spend ... recovery so we need to do it well. Inadequate sleep levels have been found ... pressure, stroke, diabetes, and even cancer. Maybe now is the best time ... could help them to manage their sleep quality? Continue ... ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... ... December 08, 2016 , ... The ability ... optogenetics — is key to exciting advances in the study and mapping of ... projected via free-space optics stimulates small, transparent organisms and excites neurons within superficial ...
(Date:12/8/2016)... Oxford Gene Technology ... Palette an anpassbaren SureSeq™ NGS-Panels mit dem Start ... ein schnelles und kostengünstiges Studium der Varianten bei ... Erkennung von Einzel-Nukleotid-Variationen (Single Nucleotide Variation, SNV) und ... Panel und ermöglicht eine individuelle Anpassung durch die ...
(Date:12/8/2016)...  Anaconda BioMed S.L., a pre-clinical stage medical device ... neuro-thrombectomy system for the treatment of Acute Ischemic Stroke ... to join its Scientific Advisory Board (SAB). The SAB ... scientific and clinical experts to Anaconda BioMed S.L., as ... ® to its clinical phase. The SAB is ...
(Date:12/8/2016)... (PRWEB) , ... December 08, ... ... announces the commercial launch of flexible packaging for their exceptionally efficient human ... bag system extends RoosterBio’s portfolio of bioprocess media products engineered to radically ...
Breaking Biology Technology: